David Lechuga-Ballesteros is Head of Innovation in Global Inhalation Product Development at AstraZeneca, where he leads the design and translation of next-generation inhaled medicines. Trained as a pharmaceutical scientist with deep expertise in spray drying, particle engineering, and solid-state formulation, his work has shaped multiple landmark respiratory and systemic therapies, including Exubera—the first inhaled insulin—and several marketed metered-dose inhalers for asthma and COPD made with engineered particle suspension technology. His research has helped establish glassy particle matrices and engineered aerosols as viable platforms for stabilizing and delivering complex molecules, while more recently advancing low–global-warming-potential propellants and inhaled biologics for respiratory disease. Lechuga-Ballesteros has authored more than 100 scientific publications, holds over 15 patents, and has served on the editorial boards of leading pharmaceutical sciences journals. He received his undergraduate training in pharmaceutics in Mexico and completed his PhD at the University of Michigan.